LEADS BIOLABS-B (09887) Reports Interim Results with Net Loss of Approximately RMB 166 Million, Down 7.8% Year-on-Year
Stock News
Aug 29
LEADS BIOLABS-B (09887) announced its interim results for 2025, with research and development costs of approximately RMB 132 million, representing a 56.9% year-on-year increase. The company recorded a loss of approximately RMB 166 million during the period, down 7.8% compared to the same period last year, with a loss per share of RMB 1.06.
According to the announcement, the increase in R&D costs was primarily attributable to: (i) increased CMC development milestone expenses, mainly related to preparatory work for the Biologics License Application (BLA) submission of LBL-024; and (ii) increased clinical development expenses, primarily due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.